<?xml version="1.0" encoding="UTF-8"?>
<ref id="tbed13734-bib-0018">
 <mixed-citation publication-type="journal" id="tbed13734-cit-0018">
  <string-name>
   <surname>Dastan</surname>, 
   <given-names>F.</given-names>
  </string-name>, 
  <string-name>
   <surname>Tabarsi</surname>, 
   <given-names>P.</given-names>
  </string-name>, 
  <string-name>
   <surname>Marjani</surname>, 
   <given-names>M.</given-names>
  </string-name>, 
  <string-name>
   <surname>Moniri</surname>, 
   <given-names>A.</given-names>
  </string-name>, 
  <string-name>
   <surname>Hashemian</surname>, 
   <given-names>S. M.</given-names>
  </string-name>, 
  <string-name>
   <surname>Tavakoli‐Ardakani</surname>, 
   <given-names>M.</given-names>
  </string-name>, &amp; 
  <string-name>
   <surname>Saffaei</surname>, 
   <given-names>A.</given-names>
  </string-name> (
  <year>2020</year>). 
  <article-title>Thalidomide against coronavirus disease 2019 (COVID‐19): A medicine with a thousand faces</article-title>. 
  <source xml:lang="en">Iranian Journal of Pharmaceutical Research</source>, 
  <volume>19</volume>, 
  <fpage>1</fpage>–
  <lpage>2</lpage>. 
  <pub-id pub-id-type="doi">10.22037/IJPR.2020.113369.14259</pub-id>
 </mixed-citation>
</ref>
